Portal de Periódicos da CAPES

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

2010; Nature Portfolio; Volume: 16; Issue: 4 Linguagem: Inglês

10.1038/nm.2112

1546-170X

Douglas W. McMillin, Jake Delmore, Ellen Weisberg, Joseph Negri, David C. Geer, Steffen Klippel, Nicholas Mitsiades, Robert Schlossman, Nikhil C. Munshi, Andrew L. Kung, James D. Griffin, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades,

Cytokine Signaling Pathways and Interactions

McMillin et al. describe a drug screening platform that takes into account the tumor microenvironment, in particular tumor-stromal interactions, enabling the screening of the antitumor activity of candidate anticancer agents in the context of such interactions. The in vitro tumor cell–specific bioluminescence imaging assay is both high throughput and scalable. Conventional anticancer drug screening is typically performed in the absence of accessory cells of the tumor microenvironment, which can profoundly alter antitumor drug activity. To address this limitation, we developed the tumor cell–specific in vitro bioluminescence imaging (CS-BLI) assay. Tumor cells (for example, myeloma, leukemia and solid tumors) stably expressing luciferase are cultured with nonmalignant accessory cells (for example, stromal cells) for selective quantification of tumor cell viability, in presence versus absence of stromal cells or drug treatment. CS-BLI is high-throughput scalable and identifies stroma-induced chemoresistance in diverse malignancies, including imatinib resistance in leukemic cells. A stroma-induced signature in tumor cells correlates with adverse clinical prognosis and includes signatures for activated Akt, Ras, NF-κB, HIF-1α, myc, hTERT and IRF4; for biological aggressiveness; and for self-renewal. Unlike conventional screening, CS-BLI can also identify agents with increased activity against tumor cells interacting with stroma. One such compound, reversine, shows more potent activity in an orthotopic model of diffuse myeloma bone lesions than in conventional subcutaneous xenografts. Use of CS-BLI, therefore, enables refined screening of candidate anticancer agents to enrich preclinical pipelines with potential therapeutics that overcome stroma-mediated drug resistance and can act in a synthetic lethal manner in the context of tumor-stroma interactions.